Udenyca Side Effects: How Long They Last and Why

Most Udenyca side effects are short-lived, resolving within a few days to roughly a week after injection, because the drug is designed to clear itself from the body once it has done its job. Udenyca (pegfilgrastim-cbqv) is a biosimilar of pegfilgrastim, the well-known white-blood-cell booster given after chemotherapy to reduce the risk of infection. The most frequently reported problems are bone pain, muscle aches, and headache, and these track closely with how the drug works and when it leaves your system. Understanding the biology behind these reactions helps explain not just what you might feel, but when you can expect relief.

What Udenyca Does and Why Side Effects Follow

Udenyca is administered 24 to 96 hours after a chemotherapy cycle to stimulate the growth of white blood cells, specifically neutrophils, the immune cells that chemotherapy depletes most aggressively.¹ The drug is essentially a longer-acting version of a naturally occurring growth factor called G-CSF. To understand the side effects, you need to appreciate that you are asking your bone marrow to ramp up production dramatically and quickly. That surge of activity inside the marrow is where most of the discomfort originates.

In clinical trials comparing the prefilled autoinjector and prefilled syringe forms of Udenyca, about three-quarters of participants in both groups experienced at least one side effect, with muscle pain, bone pain, and headache topping the list.² These were healthy volunteers, not cancer patients already weakened by chemotherapy, so the rates in real-world oncology patients can vary depending on the chemo regimen, overall health, and individual sensitivity.

Why Bone Pain Is the Signature Side Effect

Bone pain is the complaint patients ask about most, and the mechanism behind it is fairly intuitive once you picture what is happening inside your bones. G-CSF drugs like Udenyca drive rapid proliferation of neutrophil precursor cells within the bone marrow. That explosive growth increases pressure inside the marrow cavity, stretching the periosteum, the thin membrane wrapped tightly around the outside of bones. The periosteum is loaded with nerve endings, so even modest swelling triggers real pain signals. On top of that, the process kicks off a local inflammatory cascade that raises histamine levels in the area, adding to the soreness and sometimes producing a dull, deep ache that patients often describe as feeling like it is coming from “inside” their bones.

The pain tends to settle in the pelvis, lower back, sternum, and long bones of the legs, which makes sense because these are the sites with the most active bone marrow in adults. It usually begins within a day or two of the injection and peaks around days two through four, coinciding with the period when marrow activity is highest. For most people it fades over the following three to five days, though a minority report lingering soreness into the second week.

How the Drug Clears Your Body and What That Means for Side Effects

The timeline of side effects is tightly linked to how long Udenyca stays in your system, and the clearance mechanism is unusual. Most drugs are filtered out by the kidneys, but pegfilgrastim’s molecular structure essentially bypasses the kidneys entirely. Instead, it is cleared predominantly by the very neutrophils it helps create.³ This creates a built-in feedback loop: while your neutrophil count is low (which is exactly when you need the drug most), there are not enough neutrophils around to break it down, so it lingers and keeps working. Once your white blood cell count recovers, those newly minted neutrophils absorb and degrade the drug rapidly, and it vanishes from your bloodstream.

This self-regulating clearance means the drug’s duration in your body is different for every patient. Someone whose marrow recovers quickly might process Udenyca in five or six days. A person with a more suppressed marrow might carry active drug levels for over a week. Research has shown that once the absolute neutrophil count climbs back above a certain threshold, drug levels drop to essentially nothing.⁴ That is why side effects like bone pain tend to resolve around the time your blood counts normalize: the drug is literally being consumed by the cells it helped produce.

This also explains why patients receiving more intensive chemotherapy regimens sometimes report side effects lasting a bit longer. More aggressive chemo drives neutrophil counts lower and keeps them there longer, which delays the clearance of Udenyca and extends the window during which marrow expansion and bone pain can occur.

Managing Bone Pain and Muscle Aches

Over-the-counter pain relievers like ibuprofen, naproxen, or acetaminophen are the first-line approach most oncology teams suggest. These work reasonably well for mild to moderate bone pain, and many patients find that staying ahead of the pain with scheduled doses for the first few days after injection is more effective than waiting until it becomes severe.

An interesting option that has gained attention is loratadine, the over-the-counter antihistamine commonly sold for allergies. Because the inflammatory cascade in the bone marrow involves histamine release, blocking that histamine pathway can reduce the pain signal. A pilot study of cancer patients receiving G-CSF found that starting loratadine at the second chemotherapy cycle was associated with reduced pain scores compared to the first cycle when no antihistamine was used.⁵ A randomized trial specifically testing loratadine for pegfilgrastim-induced bone pain also explored this approach, though results were nuanced, with some patients in both the loratadine and placebo groups still needing additional pain medications like NSAIDs or opioids.⁶

The evidence for loratadine is not overwhelming, but many oncologists still recommend trying it because it is inexpensive, well tolerated, non-drowsy, and unlikely to interact with chemotherapy. The typical suggestion is to take 10 mg daily starting the day of or the day after the Udenyca injection and continuing for about five to seven days. It may not eliminate bone pain entirely, but it seems to take the edge off for a meaningful number of patients, and it is easy enough to add an NSAID on top if needed.

Other Common Side Effects Beyond Bone Pain

While bone pain and myalgia dominate the conversation, Udenyca can cause a handful of other reactions that are worth knowing about. Headache is consistently among the top three reported side effects in clinical trials. Fatigue, injection-site redness or soreness, and mild nausea also show up, though they are generally less bothersome and shorter-lived than the bone pain. Most of these resolve within a day or two.

Some patients notice a low-grade fever after the injection. This is not necessarily a sign of infection; the same inflammatory process that drives bone pain can also trigger mild temperature elevation. However, fever during chemotherapy always warrants a call to your oncology team, because distinguishing a drug-related fever from a neutropenic fever caused by actual infection is critical and not something to sort out on your own.

Skin reactions at the injection site are generally mild, appearing as a small area of redness, swelling, or itching that fades within a couple of days. Rarely, patients develop a more widespread rash. If that happens, your care team needs to know, both to manage the current reaction and to plan for future cycles.

Rare but Serious Reactions to Watch For

The vast majority of people tolerate Udenyca without anything more than temporary discomfort, but a few rare complications deserve mention because they require immediate medical attention.

Splenic rupture: G-CSF drugs can cause the spleen to enlarge, and in very rare instances, the spleen can rupture. Sudden sharp pain in the left upper abdomen or left shoulder tip is the warning sign. This is a medical emergency.
Acute kidney injury: A case report described severe kidney damage, including a type of inflammation called glomerulonephritis, linked to pegfilgrastim after other causes were ruled out.⁷ This is extremely uncommon, but any significant drop in urine output, unusual swelling in the legs, or unexplained fluid retention after Udenyca should prompt a call to your doctor.
Allergic reactions: Serious allergic reactions including anaphylaxis are possible but very rare. Signs include difficulty breathing, hives, swelling of the face or throat, and a rapid drop in blood pressure. These would typically occur within minutes to hours of the injection.
Acute respiratory distress syndrome (ARDS): An uncommon but dangerous inflammatory reaction in the lungs. Symptoms include sudden shortness of breath, rapid breathing, and a sense of not being able to get enough air.

These events are all rare enough that most oncology patients never encounter them, but they are the reason your team monitors you during and after treatment and why reporting any unusual symptoms matters.

Does Udenyca Cause the Same Side Effects as Neulasta?

Udenyca was approved as a biosimilar to pegfilgrastim (brand name Neulasta), and the short answer is yes, the side effect profile is essentially identical. The whole point of biosimilar development is to demonstrate that the copy behaves like the original in terms of how it moves through the body, how it stimulates white blood cells, and what adverse events it produces. Multiple randomized studies in healthy volunteers confirmed that Udenyca and the reference pegfilgrastim product show no clinically meaningful differences in safety, including immunogenicity, which is the body’s tendency to develop antibodies against the drug.⁸ An equivalence study in breast cancer patients receiving aggressive chemotherapy confirmed the same conclusion in a real-world oncology population.⁹

If you have previously taken Neulasta and are being switched to Udenyca for cost or insurance reasons, you should expect a very similar experience in terms of both effectiveness and side effects. The pharmacokinetics and pharmacodynamics matched across studies, and safety profiles including immunogenicity were comparable.¹⁰ Any differences you notice are more likely due to cycle-to-cycle variation in your own body’s response to chemotherapy than to differences between the two products.

How Side Effects Change Across Multiple Chemotherapy Cycles

Something patients often wonder is whether the side effects get worse with each round of chemo, or whether the body adapts. The answer is not entirely consistent from person to person, but a few patterns emerge. Some patients report that bone pain is worst during the first one or two cycles and improves somewhat in later rounds. Others find it stays roughly the same throughout treatment. A smaller group experiences escalating discomfort, which can reflect cumulative bone marrow stress from repeated chemotherapy cycles making each recovery more difficult.

The pilot study that tested loratadine illustrates this trajectory. Patients experienced increased daily pain after their first cycle, but once loratadine was introduced in cycle two, pain scores trended downward through subsequent cycles for most participants.⁵ Whether the improvement came from the antihistamine, from physiological adaptation, or from both is difficult to tease apart, but it suggests that adding a management strategy early can make a real difference in comfort over the course of treatment.

The self-regulating clearance mechanism described earlier also plays a role here. In later chemotherapy cycles, if your marrow becomes more heavily suppressed, neutrophil recovery takes longer, which means Udenyca circulates longer and the window of bone pain can stretch. Conversely, if your marrow handles a particular cycle well and bounces back quickly, the drug clears faster and side effects can be briefer. This variability cycle to cycle is normal and expected.

Delivery Method and Whether It Changes the Side Effect Experience

Udenyca is available as a prefilled syringe, a prefilled autoinjector, and an on-body injector that delivers the dose automatically about 27 hours after it is applied, timed to fall within the recommended post-chemo window. Patients sometimes wonder whether the delivery device affects side effects. The clinical data say no: studies comparing the autoinjector to the syringe showed nearly identical rates of side effects in both groups.² Similar bioequivalence was demonstrated for the on-body injector versus the syringe.¹

The only real difference is local to the injection site. The on-body device sits adhered to your skin for an extended period and uses a small needle that fires automatically, so localized skin irritation from the adhesive can occur and may last a day or two after the device is removed. With the manual syringe or autoinjector, injection-site reactions are the same as for any subcutaneous shot and tend to resolve quickly. Whichever delivery method you use, the systemic side effects, including bone pain, headache, and myalgia, are driven by the drug itself, not how it gets under your skin.

Long-Term Safety and the Question of Secondary Cancers

For patients receiving G-CSF support across many chemotherapy cycles, a background concern that sometimes comes up is whether these drugs increase the risk of blood cancers like myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). This question has been studied in the broader G-CSF class. A large study of older patients with non-Hodgkin lymphoma found that repeated use of filgrastim (the short-acting form) was associated with a modestly elevated risk of MDS or AML, but the same pattern was not observed for pegfilgrastim even at comparable cumulative exposure.¹¹ That is a reassuring finding, though it is worth noting that teasing apart the effects of the G-CSF drug itself from the effects of the chemotherapy it accompanies is inherently difficult, since chemotherapy is itself a known risk factor for these secondary cancers.

Because Udenyca is a biosimilar of pegfilgrastim, its long-term safety profile is expected to mirror that of the reference product. No unique long-term risks specific to Udenyca have been identified in the published data. Still, the evidence base for any biosimilar’s decades-long outcomes is inevitably thinner than for the originator, simply because biosimilars have been on the market for a shorter period. Ongoing pharmacovigilance programs continue to track outcomes in the real-world patient population.

When to Call Your Oncology Team

Mild bone pain and fatigue after an Udenyca injection are expected and manageable at home. But certain symptoms warrant a call, and it helps to know the line. Fever above 100.4°F (38°C) during the neutropenic window should always be reported promptly, regardless of whether you suspect it is drug-related or infection-related. Sudden severe abdominal pain, especially on the left side, could signal splenic enlargement. Significant shortness of breath that was not present before the injection needs evaluation. A dramatic decrease in urination or unexpected leg swelling is unusual enough to report. And any signs of a severe allergic reaction, such as throat tightness, widespread hives, or dizziness, need emergency attention.

For the far more common scenario of moderate bone pain peaking on days two through four, the combination of a scheduled NSAID and loratadine, warm compresses, and gentle movement is what most patients find helpful. Keeping a brief pain diary noting the day, severity, and what you took for relief can be surprisingly useful when you sit down with your team to plan the next cycle. Patterns often emerge that allow your providers to preemptively adjust your pain management strategy, and feeling more in control of the side effects makes the whole treatment process less daunting.